The Agreement, which will remain in effect throughout 2018, aims to facilitate patient access to therapeutic innovations under equitable conditions and ensure the sustainability of the National Health System
The excellence of the professionals, the quality of the National Health System, the commitment of the industry and the new legal framework, facilitate the clinical research against cancer in Spain
The improvement of the medicines ensures that the healthcare cost of the cancer treatment remains stable despite the increase in the incidence rates
The agreement is the result of a sustained dialogue and positive experience from the Protocol signed in 2015 and will be in force throughout 2017
During the XVI Spanish Pharmaceutical Industry meeting in Santander, representatives from the healthcare sector analyzed this plan.
His Majesty King Felipe VI hosted an audience with Farmaindustria’s Board of Directors